Targeted Sequencing Market by Product Type (Instruments, Reagents & Kits, Software & Services), Platform (Amplicon Sequencing, Hybrid Capture, Molecular Inversion Probes), End User, Application - Global Forecast 2025-2032
Description
The Targeted Sequencing Market was valued at USD 7.60 billion in 2024 and is projected to grow to USD 9.18 billion in 2025, with a CAGR of 20.58%, reaching USD 33.97 billion by 2032.
Exploring the Evolution and Core Drivers Shaping Today’s Targeted Sequencing Market to Inform Strategic Decisions
The targeted sequencing market has rapidly ascended to a cornerstone of precision medicine and genomic research, driven by technological advances that enable highly focused analysis of genomic regions of interest. Over the last decade, the cost of sequencing has plummeted while throughput and accuracy have soared, fueling demand from clinical, academic, and commercial end users alike. As genomic data becomes central to drug discovery, diagnostics, and personalized therapeutics, the need for robust targeted sequencing solutions that balance breadth of coverage with cost efficiency has never been greater.
In this landscape, benchtop sequencers are democratizing access to high-quality data within research laboratories, while high-throughput platforms continue to serve large-scale projects in pharmaceutical pipelines. Meanwhile, hybridization-based, amplicon-based, and MIP-based kits have refined sample preparation workflows, and the integration of advanced bioinformatics services and data analysis software ensures that raw sequences are translated into actionable insights. Moving forward, understanding the interplay between cost pressures, regulatory requirements, and evolving clinical applications will be essential for stakeholders seeking to navigate the complexity of this dynamic market.
How Breakthrough Chemistries and Automation Innovations Are Redefining Workflows and Competitive Dynamics in Targeted Sequencing
The competitive landscape of targeted sequencing is undergoing transformative shifts as novel chemistries, automation trends, and integrated solutions converge to redefine capabilities. Multiplex PCR and unique molecular identifier (UMI) techniques now deliver unprecedented sensitivity in detecting rare variants, while bait-based and probe-based hybrid capture methods enable comprehensive interrogation of large genomic regions. Concurrently, molecular inversion probe approaches optimized for copy number variation analysis and single nucleotide polymorphism detection are bridging the gap between research and routine diagnostics.
As platforms become more modular, vendors are collaborating to streamline workflows from sample preparation through data interpretation, reducing time to result and minimizing error rates. The growing emphasis on point-of-care sequencing is compelling instrument manufacturers to design compact systems that maintain high accuracy. This shift is complemented by bioinformatics service providers offering cloud-based solutions, enabling decentralized data access and collaboration. Altogether, these advancements are reshaping stakeholder expectations, prompting a reevaluation of partnerships, go-to-market strategies, and technology roadmaps.
Assessing the Comprehensive Impact of New United States Tariffs on Supply Chains, Pricing Strategies, and Regional Manufacturing Dynamics in Targeted Sequencing
In 2025, the imposition of United States tariffs on imported reagents, consumables, and instrumentation components has introduced supply chain complexities and cost uncertainties for global targeted sequencing stakeholders. These measures have elevated prices for hybridization-based kits and specialized MIP reagents, compelling reagent providers to evaluate local manufacturing options and strategic buffer stocks. Instrument vendors reliant on international supply chains have accelerated efforts to diversify component sourcing and negotiate long-term agreements with domestic suppliers.
Consequently, end users including academic research centers and clinical laboratories have adapted procurement strategies, staggering large orders and consolidating vendors to manage expense volatility. Despite short-term disruptions, these tariffs have also stimulated investment in regional production capabilities for reagents and kits, fostering resilience within the ecosystem. Data analysis software providers, less exposed to physical trade constraints, have capitalized on the situation by emphasizing subscription models and cloud deployment to offer cost predictability. Looking ahead, the cumulative impact of these tariffs will hinge on global trade negotiations, regional manufacturing expansions, and the elasticity of laboratory budgets.
Unveiling the Multi-Dimensional Segmentation Landscape That Defines Product Offerings Platforms User Profiles and Specialized Applications
The targeted sequencing market reveals a nuanced structure when dissected by product type, platform, end user, and application, each layer offering critical insights for stakeholders. Instruments divide into benchtop sequencers suited for smaller-scale laboratories and high-throughput sequencers engineered for large-scale operations, enabling flexibility in capital investment. Reagent and kit portfolios span amplicon-based, hybridization-based, and MIP-based approaches, catering to specific research needs from focused variant detection to broad panel analysis. Software and services range from bioinformatics pipelines tailored to specialized analytical workflows to comprehensive data analysis suites that support end-to-end project management.
On the platform front, amplicon sequencing relies on either multiplex PCR panels or UMI-based sequencing chemistries that enhance error correction and variant calling accuracy, while hybrid capture approaches leverage either baits-based or probe-based capture systems to enrich large genomic regions. Molecular inversion probe platforms distinguish themselves through dedicated modules for CNV analysis or SNP detection, offering precise, cost-efficient assays for targeted applications. End users encompass academic and research institutes, including both private and public labs, alongside hospitals and diagnostic centers, with point-of-care and reference laboratory settings, and pharmaceutical and biotechnology companies, where clinical research organizations and drug discovery units drive translational efforts. Applications span biomarker discovery-encompassing pharmacogenomic and predictive biomarker identification-to genetic diseases such as prenatal testing and rare disease diagnosis, and extend to infectious disease testing for pathogen detection and antibiotic resistance profiling, as well as oncology, where diagnostics, prognostics, and theranostics converge.
Analyzing Regional Variations in Funding Ecosystems Manufacturing Capacities and Adoption Patterns across the Americas Europe Middle East Africa and Asia-Pacific
Geographic considerations are pivotal in shaping R&D investment and adoption rates within the targeted sequencing sphere. In the Americas, robust funding for genomics research, coupled with a well-established biotech ecosystem and advanced healthcare infrastructure, drives early adoption of cutting-edge kits and high-throughput instruments. Meanwhile, European, Middle Eastern, and African regions present a mosaic of markets: Western Europe champions large-scale population sequencing initiatives, the Middle East targets genomic medicine to address region-specific genetic disorders, and Africa pursues collaborations to bolster capacity-building in infectious disease surveillance.
The Asia-Pacific region stands out for its rapid expansion in local manufacturing of sequencers and reagents, supported by governmental programs aimed at enhancing precision medicine capabilities. Countries such as China, South Korea, and Japan are not only significant end users but also emerging innovators in sequencing technologies, with a growing focus on cost-effective, scalable solutions tailored to regional disease burdens. Transitioning from mere end-user markets to hubs of technological development, these regions collectively shape the global pipeline of new kits and analytical tools.
Investigating Strategic Partnerships Technology Integration and Market Consolidation Trends among Leading Targeted Sequencing Providers
The competitive arena in targeted sequencing is characterized by a dynamic interplay between instrument manufacturers, reagent kit developers, bioinformatics service providers, and software innovators. Leading players distinguish themselves through strategic investments in vertical integration, enabling seamless workflows from sample preparation through data interpretation. Partnerships between instrument suppliers and kit manufacturers have gained traction, as combined solutions reduce validation complexity for end users and shorten time to actionable insights.
At the same time, specialist firms focusing on bioinformatics have expanded their service portfolios to include AI-driven variant annotation, cloud-based collaborative platforms, and regulatory compliance modules, meeting the growing demand for turnkey solutions. Several companies have pursued mergers and acquisitions to enhance regional footprints and diversify product pipelines, while others have launched targeted pilot programs with academic institutions to validate next-generation chemistry and software modules. As contract research organizations intensify collaboration with sequencing vendors, the market will continue to see strategic alliances that accelerate innovation and broaden the addressable user base.
Implementing Supply Chain Resilience Informatics Integration and Collaborative Validation Initiatives to Secure Competitive Advantage
Industry leaders should prioritize a multi-pronged strategy that balances technological innovation with operational agility. First, enhancing supply chain resilience by diversifying raw material sourcing and establishing regional production hubs can mitigate the volatility introduced by trade tariffs and geopolitical uncertainties. Second, integrating advanced informatics capabilities directly into sequencing platforms will streamline workflows, reduce user training overhead, and foster deeper customer engagement through value-added analytics.
Furthermore, cultivating partnerships with clinical and academic consortia to validate new panels in real-world settings will strengthen product credibility and generate compelling case studies. Simultaneously, flexible pricing models and subscription-based licensing can offer end users predictable budgeting while enabling vendors to secure recurring revenue streams. By monitoring emerging applications in oncology, rare diseases, and pathogen surveillance, companies can align R&D roadmaps with high-growth segments and position themselves ahead of competitors who remain focused solely on core offerings.
Leveraging Primary Expert Interviews and Rigorous Secondary Source Triangulation to Deliver Unbiased Actionable Insights
This research combines primary and secondary data collection methods to ensure the robustness and reliability of insights. Primary research involved in-depth interviews with key opinion leaders, including genomic researchers, clinical laboratory directors, and procurement specialists, to understand adoption drivers, pain points, and unmet needs. These qualitative inputs guided the identification of emerging trends and validated hypotheses around technology shifts and market segmentation.
Secondary research drew on peer-reviewed literature, regulatory filings, technical white papers, and patent analysis to map the evolution of chemistries, platform enhancements, and application expansions. Data triangulation methodologies were applied to reconcile discrepancies between sources, ensuring accuracy in categorizing product types, platform workflows, end-user profiles, and application use cases. Rigorous cross-validation and expert review rounds provided additional quality assurance, resulting in a comprehensive and balanced perspective on the global targeted sequencing market.
Synthesizing Market Dynamics Technological Advances and Strategic Imperatives to Chart a Sustainable Growth Path in Targeted Sequencing
As targeted sequencing technologies continue to mature, the market stands at an inflection point where integration, cost-efficiency, and regulatory alignment will dictate long-term success. Stakeholders who invest in modular, automated solutions and foster partnerships across the value chain will be best positioned to capitalize on expanding applications in personalized medicine, pathogen surveillance, and translational research. Meanwhile, navigating trade policy fluctuations and operationalizing scalable bioinformatics will separate the frontrunners from the rest.
Ultimately, the capacity to adapt to evolving end-user requirements through collaborative innovation and flexible business models will define market leadership in the years to come. By internalizing the insights on segmentation, regional dynamics, and competitive strategies outlined in this executive summary, decision-makers can refine their strategic roadmaps and secure a sustainable path to growth in the dynamic landscape of targeted sequencing.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Instruments
Benchtop Sequencers
High-Throughput Sequencers
Reagents & Kits
Amplicon-Based Kits
Hybridization-Based Kits
MIP-Based Kits
Software & Services
Bioinformatics Services
Data Analysis Software
Platform
Amplicon Sequencing
Multiplex PCR
UMI-Based Sequencing
Hybrid Capture
Baits-Based Capture
Probe-Based Capture
Molecular Inversion Probes
MIP Probes For CNV Analysis
MIP Probes For SNP Detection
End User
Academic & Research Institutes
Private Research Labs
Public Research Labs
Hospitals & Diagnostic Centers
Point-of-Care Laboratories
Reference Laboratories
Pharmaceutical & Biotechnology Companies
Clinical Research Organizations
Drug Discovery Units
Application
Biomarker Discovery
Pharmacogenomic Biomarkers
Predictive Biomarkers
Genetic Diseases
Prenatal Testing
Rare Disease Diagnosis
Infectious Diseases
Antibiotic Resistance Testing
Pathogen Detection
Oncology
Diagnostics
Prognostics
Theranostics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Illumina, Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
QIAGEN N.V.
F. Hoffmann-La Roche Ltd
BGI Genomics Co., Ltd.
Twist Bioscience Corporation
Pacific Biosciences of California, Inc.
Oxford Nanopore Technologies plc
NeoGenomics, Inc.
Note: PDF & Excel + Online Access - 1 Year
Exploring the Evolution and Core Drivers Shaping Today’s Targeted Sequencing Market to Inform Strategic Decisions
The targeted sequencing market has rapidly ascended to a cornerstone of precision medicine and genomic research, driven by technological advances that enable highly focused analysis of genomic regions of interest. Over the last decade, the cost of sequencing has plummeted while throughput and accuracy have soared, fueling demand from clinical, academic, and commercial end users alike. As genomic data becomes central to drug discovery, diagnostics, and personalized therapeutics, the need for robust targeted sequencing solutions that balance breadth of coverage with cost efficiency has never been greater.
In this landscape, benchtop sequencers are democratizing access to high-quality data within research laboratories, while high-throughput platforms continue to serve large-scale projects in pharmaceutical pipelines. Meanwhile, hybridization-based, amplicon-based, and MIP-based kits have refined sample preparation workflows, and the integration of advanced bioinformatics services and data analysis software ensures that raw sequences are translated into actionable insights. Moving forward, understanding the interplay between cost pressures, regulatory requirements, and evolving clinical applications will be essential for stakeholders seeking to navigate the complexity of this dynamic market.
How Breakthrough Chemistries and Automation Innovations Are Redefining Workflows and Competitive Dynamics in Targeted Sequencing
The competitive landscape of targeted sequencing is undergoing transformative shifts as novel chemistries, automation trends, and integrated solutions converge to redefine capabilities. Multiplex PCR and unique molecular identifier (UMI) techniques now deliver unprecedented sensitivity in detecting rare variants, while bait-based and probe-based hybrid capture methods enable comprehensive interrogation of large genomic regions. Concurrently, molecular inversion probe approaches optimized for copy number variation analysis and single nucleotide polymorphism detection are bridging the gap between research and routine diagnostics.
As platforms become more modular, vendors are collaborating to streamline workflows from sample preparation through data interpretation, reducing time to result and minimizing error rates. The growing emphasis on point-of-care sequencing is compelling instrument manufacturers to design compact systems that maintain high accuracy. This shift is complemented by bioinformatics service providers offering cloud-based solutions, enabling decentralized data access and collaboration. Altogether, these advancements are reshaping stakeholder expectations, prompting a reevaluation of partnerships, go-to-market strategies, and technology roadmaps.
Assessing the Comprehensive Impact of New United States Tariffs on Supply Chains, Pricing Strategies, and Regional Manufacturing Dynamics in Targeted Sequencing
In 2025, the imposition of United States tariffs on imported reagents, consumables, and instrumentation components has introduced supply chain complexities and cost uncertainties for global targeted sequencing stakeholders. These measures have elevated prices for hybridization-based kits and specialized MIP reagents, compelling reagent providers to evaluate local manufacturing options and strategic buffer stocks. Instrument vendors reliant on international supply chains have accelerated efforts to diversify component sourcing and negotiate long-term agreements with domestic suppliers.
Consequently, end users including academic research centers and clinical laboratories have adapted procurement strategies, staggering large orders and consolidating vendors to manage expense volatility. Despite short-term disruptions, these tariffs have also stimulated investment in regional production capabilities for reagents and kits, fostering resilience within the ecosystem. Data analysis software providers, less exposed to physical trade constraints, have capitalized on the situation by emphasizing subscription models and cloud deployment to offer cost predictability. Looking ahead, the cumulative impact of these tariffs will hinge on global trade negotiations, regional manufacturing expansions, and the elasticity of laboratory budgets.
Unveiling the Multi-Dimensional Segmentation Landscape That Defines Product Offerings Platforms User Profiles and Specialized Applications
The targeted sequencing market reveals a nuanced structure when dissected by product type, platform, end user, and application, each layer offering critical insights for stakeholders. Instruments divide into benchtop sequencers suited for smaller-scale laboratories and high-throughput sequencers engineered for large-scale operations, enabling flexibility in capital investment. Reagent and kit portfolios span amplicon-based, hybridization-based, and MIP-based approaches, catering to specific research needs from focused variant detection to broad panel analysis. Software and services range from bioinformatics pipelines tailored to specialized analytical workflows to comprehensive data analysis suites that support end-to-end project management.
On the platform front, amplicon sequencing relies on either multiplex PCR panels or UMI-based sequencing chemistries that enhance error correction and variant calling accuracy, while hybrid capture approaches leverage either baits-based or probe-based capture systems to enrich large genomic regions. Molecular inversion probe platforms distinguish themselves through dedicated modules for CNV analysis or SNP detection, offering precise, cost-efficient assays for targeted applications. End users encompass academic and research institutes, including both private and public labs, alongside hospitals and diagnostic centers, with point-of-care and reference laboratory settings, and pharmaceutical and biotechnology companies, where clinical research organizations and drug discovery units drive translational efforts. Applications span biomarker discovery-encompassing pharmacogenomic and predictive biomarker identification-to genetic diseases such as prenatal testing and rare disease diagnosis, and extend to infectious disease testing for pathogen detection and antibiotic resistance profiling, as well as oncology, where diagnostics, prognostics, and theranostics converge.
Analyzing Regional Variations in Funding Ecosystems Manufacturing Capacities and Adoption Patterns across the Americas Europe Middle East Africa and Asia-Pacific
Geographic considerations are pivotal in shaping R&D investment and adoption rates within the targeted sequencing sphere. In the Americas, robust funding for genomics research, coupled with a well-established biotech ecosystem and advanced healthcare infrastructure, drives early adoption of cutting-edge kits and high-throughput instruments. Meanwhile, European, Middle Eastern, and African regions present a mosaic of markets: Western Europe champions large-scale population sequencing initiatives, the Middle East targets genomic medicine to address region-specific genetic disorders, and Africa pursues collaborations to bolster capacity-building in infectious disease surveillance.
The Asia-Pacific region stands out for its rapid expansion in local manufacturing of sequencers and reagents, supported by governmental programs aimed at enhancing precision medicine capabilities. Countries such as China, South Korea, and Japan are not only significant end users but also emerging innovators in sequencing technologies, with a growing focus on cost-effective, scalable solutions tailored to regional disease burdens. Transitioning from mere end-user markets to hubs of technological development, these regions collectively shape the global pipeline of new kits and analytical tools.
Investigating Strategic Partnerships Technology Integration and Market Consolidation Trends among Leading Targeted Sequencing Providers
The competitive arena in targeted sequencing is characterized by a dynamic interplay between instrument manufacturers, reagent kit developers, bioinformatics service providers, and software innovators. Leading players distinguish themselves through strategic investments in vertical integration, enabling seamless workflows from sample preparation through data interpretation. Partnerships between instrument suppliers and kit manufacturers have gained traction, as combined solutions reduce validation complexity for end users and shorten time to actionable insights.
At the same time, specialist firms focusing on bioinformatics have expanded their service portfolios to include AI-driven variant annotation, cloud-based collaborative platforms, and regulatory compliance modules, meeting the growing demand for turnkey solutions. Several companies have pursued mergers and acquisitions to enhance regional footprints and diversify product pipelines, while others have launched targeted pilot programs with academic institutions to validate next-generation chemistry and software modules. As contract research organizations intensify collaboration with sequencing vendors, the market will continue to see strategic alliances that accelerate innovation and broaden the addressable user base.
Implementing Supply Chain Resilience Informatics Integration and Collaborative Validation Initiatives to Secure Competitive Advantage
Industry leaders should prioritize a multi-pronged strategy that balances technological innovation with operational agility. First, enhancing supply chain resilience by diversifying raw material sourcing and establishing regional production hubs can mitigate the volatility introduced by trade tariffs and geopolitical uncertainties. Second, integrating advanced informatics capabilities directly into sequencing platforms will streamline workflows, reduce user training overhead, and foster deeper customer engagement through value-added analytics.
Furthermore, cultivating partnerships with clinical and academic consortia to validate new panels in real-world settings will strengthen product credibility and generate compelling case studies. Simultaneously, flexible pricing models and subscription-based licensing can offer end users predictable budgeting while enabling vendors to secure recurring revenue streams. By monitoring emerging applications in oncology, rare diseases, and pathogen surveillance, companies can align R&D roadmaps with high-growth segments and position themselves ahead of competitors who remain focused solely on core offerings.
Leveraging Primary Expert Interviews and Rigorous Secondary Source Triangulation to Deliver Unbiased Actionable Insights
This research combines primary and secondary data collection methods to ensure the robustness and reliability of insights. Primary research involved in-depth interviews with key opinion leaders, including genomic researchers, clinical laboratory directors, and procurement specialists, to understand adoption drivers, pain points, and unmet needs. These qualitative inputs guided the identification of emerging trends and validated hypotheses around technology shifts and market segmentation.
Secondary research drew on peer-reviewed literature, regulatory filings, technical white papers, and patent analysis to map the evolution of chemistries, platform enhancements, and application expansions. Data triangulation methodologies were applied to reconcile discrepancies between sources, ensuring accuracy in categorizing product types, platform workflows, end-user profiles, and application use cases. Rigorous cross-validation and expert review rounds provided additional quality assurance, resulting in a comprehensive and balanced perspective on the global targeted sequencing market.
Synthesizing Market Dynamics Technological Advances and Strategic Imperatives to Chart a Sustainable Growth Path in Targeted Sequencing
As targeted sequencing technologies continue to mature, the market stands at an inflection point where integration, cost-efficiency, and regulatory alignment will dictate long-term success. Stakeholders who invest in modular, automated solutions and foster partnerships across the value chain will be best positioned to capitalize on expanding applications in personalized medicine, pathogen surveillance, and translational research. Meanwhile, navigating trade policy fluctuations and operationalizing scalable bioinformatics will separate the frontrunners from the rest.
Ultimately, the capacity to adapt to evolving end-user requirements through collaborative innovation and flexible business models will define market leadership in the years to come. By internalizing the insights on segmentation, regional dynamics, and competitive strategies outlined in this executive summary, decision-makers can refine their strategic roadmaps and secure a sustainable path to growth in the dynamic landscape of targeted sequencing.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Product Type
Instruments
Benchtop Sequencers
High-Throughput Sequencers
Reagents & Kits
Amplicon-Based Kits
Hybridization-Based Kits
MIP-Based Kits
Software & Services
Bioinformatics Services
Data Analysis Software
Platform
Amplicon Sequencing
Multiplex PCR
UMI-Based Sequencing
Hybrid Capture
Baits-Based Capture
Probe-Based Capture
Molecular Inversion Probes
MIP Probes For CNV Analysis
MIP Probes For SNP Detection
End User
Academic & Research Institutes
Private Research Labs
Public Research Labs
Hospitals & Diagnostic Centers
Point-of-Care Laboratories
Reference Laboratories
Pharmaceutical & Biotechnology Companies
Clinical Research Organizations
Drug Discovery Units
Application
Biomarker Discovery
Pharmacogenomic Biomarkers
Predictive Biomarkers
Genetic Diseases
Prenatal Testing
Rare Disease Diagnosis
Infectious Diseases
Antibiotic Resistance Testing
Pathogen Detection
Oncology
Diagnostics
Prognostics
Theranostics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Illumina, Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
QIAGEN N.V.
F. Hoffmann-La Roche Ltd
BGI Genomics Co., Ltd.
Twist Bioscience Corporation
Pacific Biosciences of California, Inc.
Oxford Nanopore Technologies plc
NeoGenomics, Inc.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid integration of custom targeted sequencing panels for precision oncology and personalized treatment decision making
- 5.2. Expansion of multiplexed targeted sequencing assays for comprehensive microbial pathogen detection in clinical labs
- 5.3. Emergence of single-cell targeted sequencing technologies to resolve cellular heterogeneity in tumor microenvironments
- 5.4. Implementation of long-read targeted sequencing approaches to detect structural variants and complex genomic rearrangements
- 5.5. Growth of on-chip microfluidic targeted sequencing platforms enabling high-throughput sample processing and reduced costs
- 5.6. Increasing application of targeted sequencing in noninvasive prenatal testing for early detection of fetal chromosomal abnormalities
- 5.7. Advancements in bioinformatic pipelines for enhanced sensitivity and specificity in targeted sequencing data analysis workflows
- 5.8. Shift toward integrated targeted sequencing and digital pathology solutions for comprehensive molecular diagnostics
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Targeted Sequencing Market, by Product Type
- 8.1. Instruments
- 8.1.1. Benchtop Sequencers
- 8.1.2. High-Throughput Sequencers
- 8.2. Reagents & Kits
- 8.2.1. Amplicon-Based Kits
- 8.2.2. Hybridization-Based Kits
- 8.2.3. MIP-Based Kits
- 8.3. Software & Services
- 8.3.1. Bioinformatics Services
- 8.3.2. Data Analysis Software
- 9. Targeted Sequencing Market, by Platform
- 9.1. Amplicon Sequencing
- 9.1.1. Multiplex PCR
- 9.1.2. UMI-Based Sequencing
- 9.2. Hybrid Capture
- 9.2.1. Baits-Based Capture
- 9.2.2. Probe-Based Capture
- 9.3. Molecular Inversion Probes
- 9.3.1. MIP Probes For CNV Analysis
- 9.3.2. MIP Probes For SNP Detection
- 10. Targeted Sequencing Market, by End User
- 10.1. Academic & Research Institutes
- 10.1.1. Private Research Labs
- 10.1.2. Public Research Labs
- 10.2. Hospitals & Diagnostic Centers
- 10.2.1. Point-of-Care Laboratories
- 10.2.2. Reference Laboratories
- 10.3. Pharmaceutical & Biotechnology Companies
- 10.3.1. Clinical Research Organizations
- 10.3.2. Drug Discovery Units
- 11. Targeted Sequencing Market, by Application
- 11.1. Biomarker Discovery
- 11.1.1. Pharmacogenomic Biomarkers
- 11.1.2. Predictive Biomarkers
- 11.2. Genetic Diseases
- 11.2.1. Prenatal Testing
- 11.2.2. Rare Disease Diagnosis
- 11.3. Infectious Diseases
- 11.3.1. Antibiotic Resistance Testing
- 11.3.2. Pathogen Detection
- 11.4. Oncology
- 11.4.1. Diagnostics
- 11.4.2. Prognostics
- 11.4.3. Theranostics
- 12. Targeted Sequencing Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Targeted Sequencing Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Targeted Sequencing Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Illumina, Inc.
- 15.3.2. Thermo Fisher Scientific Inc.
- 15.3.3. Agilent Technologies, Inc.
- 15.3.4. QIAGEN N.V.
- 15.3.5. F. Hoffmann-La Roche Ltd
- 15.3.6. BGI Genomics Co., Ltd.
- 15.3.7. Twist Bioscience Corporation
- 15.3.8. Pacific Biosciences of California, Inc.
- 15.3.9. Oxford Nanopore Technologies plc
- 15.3.10. NeoGenomics, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
